Traders Sell Gilead Sciences (GILD) on Strength (GILD)

Investors sold shares of Gilead Sciences, Inc. (NASDAQ:GILD) on strength during trading on Friday. $53.63 million flowed into the stock on the tick-up and $122.90 million flowed out of the stock on the tick-down, for a money net flow of $69.27 million out of the stock. Of all equities tracked, Gilead Sciences had the 0th highest net out-flow for the day. Gilead Sciences traded up $0.51 for the day and closed at $70.84

Several analysts recently commented on GILD shares. BidaskClub cut shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Saturday, March 3rd. Barclays reaffirmed an “overweight” rating and set a $95.00 price objective (up previously from $90.00) on shares of Gilead Sciences in a research report on Tuesday, March 6th. Zacks Investment Research lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, April 11th. Credit Suisse Group set a $80.00 price objective on shares of Gilead Sciences and gave the company a “hold” rating in a research report on Tuesday, April 17th. Finally, ValuEngine lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, May 2nd. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, fifteen have issued a buy rating and two have given a strong buy rating to the company. Gilead Sciences presently has an average rating of “Buy” and a consensus target price of $88.22.

The company has a market capitalization of $91.45 billion, a PE ratio of 8.28, a price-to-earnings-growth ratio of -6.12 and a beta of 1.15. The company has a current ratio of 2.84, a quick ratio of 2.75 and a debt-to-equity ratio of 1.32.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, May 1st. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.67 by ($0.19). The company had revenue of $5.09 billion during the quarter, compared to analyst estimates of $5.40 billion. Gilead Sciences had a return on equity of 45.49% and a net margin of 14.03%. The company’s revenue was down 21.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.23 EPS. equities research analysts forecast that Gilead Sciences, Inc. will post 5.75 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 28th. Stockholders of record on Friday, June 15th were paid a $0.57 dividend. The ex-dividend date of this dividend was Thursday, June 14th. This represents a $2.28 annualized dividend and a dividend yield of 3.22%. Gilead Sciences’s payout ratio is 26.64%.

In other Gilead Sciences news, Director John Francis Cogan sold 5,833 shares of Gilead Sciences stock in a transaction on Friday, April 6th. The shares were sold at an average price of $74.47, for a total transaction of $434,383.51. Following the sale, the director now owns 58,452 shares in the company, valued at $4,352,920.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction on Tuesday, May 1st. The stock was sold at an average price of $72.19, for a total transaction of $3,609,500.00. Following the sale, the director now owns 3,067,762 shares in the company, valued at approximately $221,461,738.78. The disclosure for this sale can be found here. Insiders have sold 179,168 shares of company stock worth $12,789,233 in the last quarter. Corporate insiders own 1.30% of the company’s stock.

Several large investors have recently modified their holdings of the company. Brown Advisory Inc. boosted its stake in shares of Gilead Sciences by 15.3% in the 1st quarter. Brown Advisory Inc. now owns 60,197 shares of the biopharmaceutical company’s stock valued at $4,538,000 after purchasing an additional 8,006 shares in the last quarter. Avalon Advisors LLC boosted its stake in shares of Gilead Sciences by 16.5% in the 1st quarter. Avalon Advisors LLC now owns 363,934 shares of the biopharmaceutical company’s stock valued at $27,437,000 after purchasing an additional 51,569 shares in the last quarter. Mount Yale Investment Advisors LLC acquired a new stake in shares of Gilead Sciences in the 1st quarter valued at $355,000. Cynosure Advisors LLC boosted its stake in shares of Gilead Sciences by 133.5% in the 1st quarter. Cynosure Advisors LLC now owns 20,802 shares of the biopharmaceutical company’s stock valued at $1,568,000 after purchasing an additional 11,892 shares in the last quarter. Finally, Altium Wealth Management LLC bought a new position in shares of Gilead Sciences in the first quarter valued at about $354,000. Institutional investors own 77.65% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands.

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply